Shane Kovacs
Director of Finance/CFO chez OLEMA PHARMACEUTICALS, INC.
Fortune : 5 M $ au 31/03/2024
Profil
Shane William Charles Kovacs is currently the Director at Knopp Neurosciences, Inc. and the Chief Operating & Financial Officer at Olema Pharmaceuticals, Inc. He previously worked as the Director at Knopp Biosciences LLC, Managing Director-Health Care Investment Banking at Credit Suisse (Australia) Ltd.
from 2002 to 2013, Director at PTC Therapeutics International Ltd., CFO & Head-Corporate Development at PTC Therapeutics, Inc. from 2015 to 2017, Associate at National Bank Financial, Inc., Head-Biotechnology at RBC Capital Markets, Inc. from 2017 to 2018, and Chief Financial & Business Officer at BlueRock Therapeutics LP from 2018 to 2020.
He has an undergraduate degree from Queen's University and an MBA from Richard Ivey School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/02/2024 | 484 987 ( 0,87% ) | 5 M $ | 31/03/2024 |
Postes actifs de Shane Kovacs
| Sociétés | Poste | Début |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Director of Finance/CFO | 01/06/2020 |
Knopp Neurosciences, Inc.
 Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Director/Board Member | - |
Anciens postes connus de Shane Kovacs
| Sociétés | Poste | Fin |
|---|---|---|
BlueRock Therapeutics LP
 BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company based in Cambridge, MA. The private company is focused on creating cellular medicines to reverse devastating diseases such as neurological, cardiovascular, immunological, and ophthalmic diseases. BlueRock Therapeutics's lead clinical program, Bemdaneprocel, is in phase I clinical trials for Parkinson's disease. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. The company was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. | Director of Finance/CFO | 01/03/2020 |
RBC Capital Markets, Inc.
 RBC Capital Markets, Inc. Investment ManagersFinance Part of Royal Bank of Canada, RBC Capital Markets, Inc. provides investment advice. The private company is based in Albany, NY. | Corporate Officer/Principal | 01/09/2018 |
Credit Suisse (Australia) Ltd.
 Credit Suisse (Australia) Ltd. Investment Banks/BrokersFinance Credit Suisse (Australia) Ltd. (Credit Suisse Australia) is a broker/dealer firm headquartered in Sydney, Australia. The firm was founded in 1999 and is a subsidiary of Credit Suisse AG, which is owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Australia offers global securities sales, trading and execution, prime brokerage, underwriting, and comprehensive investment research for corporate and institutional investors. | Corporate Officer/Principal | 01/05/2013 |
| PTC Therapeutics International Ltd. | Director/Board Member | - |
Knopp Biosciences LLC
 Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Director/Board Member | - |
Formation de Shane Kovacs
| Queen's University | Undergraduate Degree |
| Richard Ivey School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PTC THERAPEUTICS, INC. | Health Technology |
| OLEMA PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
Knopp Neurosciences, Inc.
Knopp Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Knopp Neurosciences, Inc. operates as a drug discovery and development company. It focused on delivering breakthrough treatments in neurological disorders. It operates through three areas: inflammation discovery platform, mitochondrial discovery platform, and ion channel discovery platform. The company was founded by Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
Knopp Biosciences LLC
Knopp Biosciences LLC Pharmaceuticals: MajorHealth Technology Knopp Biosciences LLC engages in the operation of a drug discovery and development company. It offers dexpramipexole product, an orally bioavaliable small molecule in development treatment of asthma, eosinophil-associated disorders and amyotrophic lateral sclerosis (ALS) disease. The company was founded by Robert Bowser and Gregory T. Hebrank in 2004 and is headquartered in Pittsburgh, PA. | Health Technology |
National Bank Financial, Inc.
 National Bank Financial, Inc. Investment ManagersFinance National Bank Financial, Inc. (NBF) is a Canadian mutual fund manager headquartered in Montréal, Quebec. The firm was founded in 1902 and is a direct subsidiary of National Bank Acquisition Holding, Inc., ultimately owned by National Bank of Canada (TSX: NA). NBF is an integrated firm that combines retail advisory and brokerage services with institutional brokerage, investment banking, corporate finance and securities clearing services for third parties. | Finance |
Credit Suisse (Australia) Ltd.
Credit Suisse (Australia) Ltd. Investment Banks/BrokersFinance Credit Suisse (Australia) Ltd. (Credit Suisse Australia) is a broker/dealer firm headquartered in Sydney, Australia. The firm was founded in 1999 and is a subsidiary of Credit Suisse AG, which is owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Australia offers global securities sales, trading and execution, prime brokerage, underwriting, and comprehensive investment research for corporate and institutional investors. | Finance |
RBC Capital Markets, Inc.
RBC Capital Markets, Inc. Investment ManagersFinance Part of Royal Bank of Canada, RBC Capital Markets, Inc. provides investment advice. The private company is based in Albany, NY. | Finance |
| PTC Therapeutics International Ltd. | |
BlueRock Therapeutics LP
BlueRock Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, BlueRock Therapeutics LP is a clinical stage cell therapy company based in Cambridge, MA. The private company is focused on creating cellular medicines to reverse devastating diseases such as neurological, cardiovascular, immunological, and ophthalmic diseases. BlueRock Therapeutics's lead clinical program, Bemdaneprocel, is in phase I clinical trials for Parkinson's disease. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed cell & gene therapy platform. The company's culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that they are all part of something bigger than themselves. The company was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. | Commercial Services |
